ACADIA Pharmaceuticals
Committed to developing treatments for neurological disorders.
Launch date
Employees
Market cap
AUD4.2b
Enterprise valuation
AUD3.5b (Public information from Sep 2024)
Share price
$16.42 ACAD
San Diego California (HQ)
Financials
Estimates*
| USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Revenues | 442m | 484m | 517m | 726m | 952m | 1.1b | 1.2b |
| % growth | 30 % | 10 % | 7 % | 40 % | 31 % | 11 % | 11 % |
| EBITDA | (287m) | (170m) | (224m) | (67.8m) | 72.2m | 154m | 313m |
| % EBITDA margin | (65 %) | (35 %) | (43 %) | (9 %) | 8 % | 14 % | 27 % |
| Profit | (282m) | (168m) | (216m) | (61.3m) | 88.2m | 156m | 277m |
| % profit margin | (64 %) | (35 %) | (42 %) | (8 %) | 9 % | 15 % | 23 % |
| EV / revenue | 17.8x | 6.7x | 4.2x | 6.5x | 2.3x | 1.9x | 1.5x |
| EV / EBITDA | -27.4x | -19.0x | -9.7x | -69.3x | 30.5x | 13.1x | 5.5x |
| R&D budget | 319m | 239m | 362m | 352m | - | - | - |
| R&D % of revenue | 72 % | 49 % | 70 % | 48 % | - | - | - |
Source: Dealroom estimates
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | N/A | - | |
$6.0m | Series A | ||
$3.0m | Series B | ||
$10.7m | Series D | ||
N/A | Grant | ||
$25.0m | Series F | ||
| N/A | N/A | IPO | |
$10.0m | Post IPO Equity | ||
$20.0m | Post IPO Equity | ||
$15.0m | Post IPO Equity | ||
| N/A | $86.4m | Post IPO Equity | |
* | N/A | $316m | Post IPO Equity |
* | N/A | $288m | Post IPO Equity |
| Total Funding | AUD69.1m | ||
Related Content
Recent News about ACADIA Pharmaceuticals
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.
Investments by ACADIA Pharmaceuticals
Edit
ACQUISITION by ACADIA Pharmaceuticals Aug 2020